Barriers and facilitators to representative acute leukemia trial participation at National Cancer Institute-designated comprehensive cancer centers
Patients and clinicians identified actionable steps to improve trial participation that address the unique challenges for adults with acute leukemia. A multi-pronged and disease-specific approach is needed to achieve representative acute leukemia clinical trials.
Authors
- Alice S. Mims (ORCID: https://orcid.org/0000-0002-8971-2199)
- Eric Blackstone (ORCID: https://orcid.org/0000-0003-1780-514X)
- Anna Revette (ORCID: https://orcid.org/0000-0002-4590-755X)
- Andrew Hantel (ORCID: https://orcid.org/0000-0001-9612-3643)
- Jane E. Roberts (ORCID: https://orcid.org/0000-0001-6924-0596)
- Christopher S. Lathan (ORCID: https://orcid.org/0000-0003-4549-3040)
- Daniel J. DeAngelo (ORCID: https://orcid.org/0000-0001-7865-2306)
- Gregory Alan Abel (ORCID: https://orcid.org/0000-0003-1100-2813)
Institutions
- Harvard University (US)
- Center for Practical Bioethics (US)
- Dana-Farber Cancer Institute (US)
- Bioethics International (US)
- The Ohio State University (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1093/oncolo/oyaf241
- Primary Topic
- Ethics in Clinical Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00